Global CDMO giant Catalent, which has been struggling through difficult financial times, added more biologic processes to its OneBio platform, which features capabilities for antibody and recombinant ...

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, ...

FREMONT, Calif., June 29, 2020 /PRNewswire/ -- Eurofins DiscoverX, the products company of Eurofins Discovery, today announced the expansion of their CRO Certification Program for Bioassays with ...

Argus had upgraded Catalent (NYSE:CTLT) to buy, citing the company’s transition from COVID products to commercializing biologics and gene therapies. The research group noted that Catalent is partnered ...

SOMERSET, N.J., May 31, 2018 /PRNewswire-PRWeb/ -- Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer ...

Catalent announced a $12 million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City, MO. Two new analytical development laboratories will be ...

Catalent provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a ...

Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has expanded its integrated development, manufacturing and supply ...

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene ...

Catalent, Inc. CTLT, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Ricardo Zayas as Senior Vice President, ...

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...